On Monday, shares of Corona Remedies and Wakefit Innovations will make their debut on the stock exchanges. The grey market is indicating a positive start for both companies, but with different levels of investor confidence.
Corona Remedies is expected to have a strong listing, with a grey market premium (GMP) of around 28%. This suggests that investors are expecting significant gains on the first day of trading. The company's IPO was subscribed to 144.5 times overall, with strong participation from all investor categories.
The company operates in areas such as women's healthcare, cardio-diabetes, pain management, and urology. It has built a diversified portfolio of 71 brands and a wide distribution network spanning 22 states, supported by more than 2,600 medical representatives.
In contrast, Wakefit Innovations is entering the market with a more tempered investor response. The company's IPO was subscribed to 2.52 times overall, with retail investors subscribing just over three times their allocation. The GMP is around 4%, indicating a more muted debut.
Wakefit Innovations is a well-known direct-to-consumer brand in the home and sleep solutions space, offering mattresses, furniture, and furnishings through a mix of online channels and physical stores. While revenue growth has remained strong, profitability has been uneven.
The difference in GMPs between the two listings highlights current investor preferences. Companies with consistent profitability and clear earnings visibility are commanding higher enthusiasm, while consumer-facing, growth-oriented businesses are being approached with greater caution.
Both listings will be closely watched by investors and market analysts, as they provide insight into the current state of the stock market and investor sentiment towards different types of businesses.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram